‘Cutting red tape,’ mental health and primary care on the health docket this fall
Amid the Liberals’ focus on building a stronger economy, Health Minister Marjorie Michel’s office says that faster access to new medicines and supporting researchers are priorities.
Canada at risk of collateral damage in U.S. drug pricing war
A proactive and co-ordinated strategy from the government is essential to safeguard both access and affordability to medicines for the long term.
U.S. tariffs on pharmaceuticals could complicate an already complex supply chain
Drug companies could begin questioning whether to manufacture drugs or conduct clinical trials in Canada, says Life Sciences Ontario CEO.
A different ‘philosophy’ steers new drug pricing guidelines, says top PMPRB bureaucrat after contentious path to rule changes
Guideline changes became necessary after Justin Trudeau’s government chose to amend the Patented Medicines Regulations, a process beset with legal challenges and many delays.
Canada’s next top doctor must be a ‘focal point’ for public health amid changes in the U.S., concerns about next pandemic
Dr. Theresa Tam has left the job of chief public health officer after eight years. Her successor will have to contend with a change in the U.S.’ public health approach, vaccine hesitancy among Canadians and the need to always be ready for the next global outbreak.
From momentum to leadership: securing Canada’s biotech future
To lead in this space, Canada needs a globally competitive investment climate, and a best-in-class regulatory system.
Biotech
Harnessing the power of Canada’s growing biotechnology industry: a perspective from the West
Government investment and policy can help ensure groundbreaking technologies remain in Canada when companies scale up their production especially for international distribution.
Biotechnology: an opportunity balanced on a knife’s edge
To fully harness the benefits of a thriving biotechnology industry, it is critical we act to address the challenges that threaten it.
Biotechnology must factor into a broader Canadian industrial policy
Governments should focus on supporting basic research, helping startups, and funding the scale-up of growth companies.
